Our Pipeline


Pre-clinical POC

Phase 1

Phase 2

Phase 3

SFX-01-Breast Cancer
Research work is ongoing on the role of SFX-01 in relation to the development of resistance to certain CDK4/6 inhibitors. Read more +
SFX-01- Neurodevelopmental Disorders
TheraCryf has licensed the global rights for lead asset SFX‐01 in neurodevelopmental disorders and schizophrenia to Stalicla Read more +
SFX-01- Glioblastoma
Strong preclinical data have been generated in orthotopic models of GBM. Further preclinical work is underway under a grant to the Erasmus Medical Centre, Rotterdam, NL. A window of opportunity clinical study is being designed under the same grant. Read more +
SFX-01- Rhabdomyosarcoma
Preclinical data has demonstrated that SFX-01 is effective in in vitro models of rhabdomyosarcoma. Further experiments have show efficacy of SFX-01 in vivo also. Read more +
NCE - Ox1 in Addiction
TheraCryf has a candidate orexin 1 antagonist targeting addictive behaviours with preclinical proof of concept in a model of Binge Eating Disorder (BED) Read more +
NCE - Ox1 in Anxiety
TheraCryf has a candidate orexin 1 antagonist targeting anxiety where orexin antagonists have already demonstrated preliminary effectiveness in man. Read more +
NCE - DAT in Fatigue and Narcolepsy
TheraCryf has a candidate molecule inhibiting the brain dopamine active transport system (DAT) with preclinical proof of concept in models of fatigue and of narcolepsy. Read more +

Licensing & Partnerships

Licensing Strategy
TheraCryf is open to out-licensing and collaboration discussions on all of its programmes and is seeking to expand its pipeline through in-licensing or partnerships.

Please contact us for more information.

Existing Partnerships

TheraCryf has licensed the global rights for lead asset SFX‐01 in neurodevelopmental disorders and schizophrenia to Stalicla.

Stalicla will use its proprietary precision medicine platform to identify specific phenotypes of autism spectrum disorder (ASD). TheraCryf and Stalicla will collaborate initially on a clinical programme in ASD, with Stalicla funding all clinical development activities.

TheraCryf retains the global rights for all other indications.




TheraCryf is seeking to expand its presence through in-licensing or partnerships. Please contact us for more information.
Contact Us

SFX-01 - Breast Cancer

Breast cancer is the largest cause of cancer deaths in women worldwide.  In around 75% of breast cancers, the hormone oestrogen plays a key part in tumour growth.

TheraCryf sponsored a Phase II trial [STEM – SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer] in patients with ER+, HER2-ve metastatic breast cancer (mBC).  The study enrolled 46 patients with oestrogen-positive mBC who had all previously received treatment with either tamoxifen, an aromatase inhibitor (AI) or fulvestrant. Prior to entry to the STEM trial, patients previously responded to their current hormone therapy for at least six months but then presented with progressive disease, thereby demonstrating the start of resistance to the hormone therapy.

Once entered into the trial, patients continued to receive their failing hormone therapy in addition to SFX-01 and had regular scans through to week 24. Patients discontinued the trial when one of the scans shows disease progression, or at week 24. Those patients who did not progress by week 24 were allowed to continue to receive treatment in an extension phase until disease progression.

Positive results were announced in March 2019 and the headlines were:

  1. Evidence of anti-cancer activity via tumour shrinkage and disease stabilisation.

  2. 24% of patients showed a durable clinical benefit for at least six months, despite the late stage of disease and patients’ established resistance to hormone therapy. Of these, five patients received SFX-01 for over 12 months and one patient remained on treatment for over 18 months.

  3. A favourable side effect profile for an anti-cancer drug.

See full STEM information, including posters and presentations.

TheraCryf is continuing investigation into how SFX-01, in combination with other treatments, can improve outcomes for patients with HR+ breast tumours that have become resistant to other therapies.  This includes research into STAT3 and pSTAT3, a protein that controls transcription of information from DNA to messenger RNA; and SHP2, a non-receptor protein tyrosine phosphatase that is associated with many cancers including breast cancer.

SFX-01 - Neurodevelopmental Disorders

Autism spectrum disorder is a group of neurodevelopmental disorders (NDDs) currently diagnosed based on core behavioural features, without specific biological criteria.

Previous studies with other sources of sulforaphane have shown evidence of clinical efficacy in improving symptoms of ASD (e.g. Singh et al 2014). However, patient heterogeneity provides a challenge in identifying those individuals most likely to respond to therapy.

Stalicla specialises in the identification of specific phenotypes of autism spectrum disorder (ASD) and has a unique, proprietary technology to identify ASD patients who are most likely to respond to SFX‐01.  This screening approach has already been used successfully to identify ideal patients for other ASD drug trials and is a key differentiator for Stalicla in developing drugs for such a wide spectrum disorder as ASD.

TheraCryf’s partnership with Stalicla will enable the targeting of patient groups most likely to benefit from SFX‐01, not only de‐risking the clinical development but potentially bringing a therapeutic option to those individuals who are currently underserved, in a quick and efficient manner.

SFX-01 - Glioblastoma

Strong preclinical data has been generated in a new solid tumour indication, glioblastoma (GBM), with further preclinical work underway and designs for a Phase Ib/IIa trial being assessed.

Glioma is the most common form of brain tumour affecting around five per 100,000 people. The more severe, grade IV classification, glioblastoma, is a very serious form of brain tumour representing 45% of all cases and has a poor prognosis with median survival of around 14 months. The five-year survival of the severe grades is 5%.

The data generated for SFX-01 in standard preclinical models and orthotopic models (where glioma cells are implanted in brain tissue representing a more disease-relevant model) show tumour shrinkage and significantly extended survival times. SFX-01 was also found to potentiate (i.e. substantially increase) the therapeutic effect of radiotherapy in these models.

The therapeutic options for glioma are limited to surgery, radiotherapy and the one drug widely available, temozolomide. There is a clear unmet need for more treatments for use in conjunction with the current standard of care.

TheraCryf is collaborating with Dr Marjolein Geurts, neuro-oncologist at the Erasmus University Medical Center on a project that will investigate the use of SFX-01 in pre-clinical glioblastoma models, followed by a clinical Investigator Sponsored Study (ISS), aiming to establish the presence of the drug in human brain tumours and engagement with relevant molecular targets in excised tumour tissue. The studies, which are funded by a grant awarded by the KWF Dutch Cancer Society, formally commenced on 1 October 2023.

The US Food and Drug Administration (”FDA”) has granted an Orphan Drug Designation (“ODD”) for the use of SFX-01 to treat malignant glioma.  This is usually granted when there are fewer than 200,000 patients with a given disease in the United States and there is a scientific rationale for potential use of the product in that condition. As well as recognising the relative rareness of a disease, OD confers intellectual property cover to an investigational drug in the form of data protection at the time of approval of a new drug application, which is additional to any patent cover in force.  Tax credits are also possible on eventual US sales of an approved orphan drug.

SFX-01 - Rhabdomyosarcoma

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood, representing about 3-4% of all paediatric cancers and 50% of all soft tissue sarcoma in children. Treatment can include any combination of surgery, radiotherapy and chemotherapy, however the 5-year event-free survival rate for RMS patients with metastatic disease is about 30%.

In vitro studies demonstrated the antitumor activity of SFX-01 in two preclinical models of RMS tumours. In particular, SFX-01 treatment significantly reduced the proliferation and migration of RMS cells and enhanced the effects mediated by radiotherapy. The results suggest that the combined approach using SFX-01 and radiotherapy might have therapeutic benefits, mainly in the clinical management of patients with aggressive RMS disease.

An abstract published on ESMO Open provides further information about the study.

NCE - Ox1 in Addiction

There are a number of addictive behaviours that represent significant unmet medical needs and require novel treatments.

Binge Eating

Binge eating is an eating disorder where a person feels compelled to overeat on a regular  basis through regular “binges” or consumption of very large quantities of food over a very short period of time, even when they are not hungry. The condition tends to develop first in young adults, although many people do not seek help until they are in their 30s or 40s.

There is a 1 in 30 to 1 in 50 chance of a person developing binge eating disorder at some point during their life and it can lead to a variety of health problems that can, in extreme circumstances, be life-threatening. Whilst more women suffer from the condition than men, binge eating is not particularly uncommon in men with the prevalence ratio of approximately 1.5 women for every man with the disorder.

TheraCryf has a candidate orexin 1 antagonist at late preclinical stage targeting addictive behaviours.


NCE - Ox1 in Anxiety

Anxiety disorders constitute one of the most common groups of psychiatric disorders with a lifetime prevalence of 14.5–33.7%. Despite efficacious pharmacological and psychological treatments, first line treatment is often not effective.

Clinical trials using orexin 1 antagonists have demonstrated alleviation of panic and anxiety in human models of these conditions.

TheraCryf has a candidate orexin 1 antagonist at late preclinical stage targeting anxiety.

NCE - DAT in Fatigue and Narcolepsy

Fatigue is a feature of several chronic diseases of the central and peripheral nervous system.

The pathophysiology of central fatigue is complex and often not well-defined. Patients often define this central fatigue as a subjective sensation of weariness, increasing sense of effort, mismatch between effort expended and actual performance, or exhaustion.

TheraCryf has a candidate molecule DAT inhibitor at late preclinical stage targeting fatigue and narcolepsy.